Livagen vs GHRP-2
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
- GHRP-2 is a potent synthetic hexapeptide that stimulates growth hormone release by activating ghrelin receptors in the pituitary and hypothalamus. It produces one of the strongest GH pulses among GHRPs, though unlike Ipamorelin it does cause modest increases in cortisol and prolactin.
- Half-Life
- Short (minutes); gene-regulatory effects are sustained
- 15–60 minutes
- Admin Route
- SubQ, Oral
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 100–300 mcg
- Frequency
- Daily for 10–30 days
- 2–3 times daily
- Key Benefits
- Supports hepatocyte regeneration and liver tissue repair
- Normalizes liver cell protein synthesis
- Immune modulation via thymic activity
- Potential benefits in chronic hepatitis and liver aging
- Anti-aging effects on hepatic tissue
- May support liver recovery after toxic insult or alcohol damage
- Complementary to NAD+ and glutathione in liver health protocols
- Strong GH pulse stimulation
- Increased IGF-1 levels
- Enhanced muscle growth and recovery
- Improved fat metabolism
- Better sleep quality
- Increased bone density
- Enhanced appetite (less pronounced than GHRP-6)
- Anti-aging effects via GH axis optimization
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hepatotoxic effects reported at standard doses
- Increased appetite
- Water retention
- Elevated cortisol (modest)
- Elevated prolactin (modest)
- +2 more
- Stacks With
- —
- —